HRP20150136T1 - Postupak dobivanja 2-[4-(3- i 2-fluorbenziloksi)benzilamino]propanamida - Google Patents

Postupak dobivanja 2-[4-(3- i 2-fluorbenziloksi)benzilamino]propanamida

Info

Publication number
HRP20150136T1
HRP20150136T1 HRP20150136TT HRP20150136T HRP20150136T1 HR P20150136 T1 HRP20150136 T1 HR P20150136T1 HR P20150136T T HRP20150136T T HR P20150136TT HR P20150136 T HRP20150136 T HR P20150136T HR P20150136 T1 HRP20150136 T1 HR P20150136T1
Authority
HR
Croatia
Prior art keywords
fluorobenzyloxy
propanamide
benzylamino
preparation
Prior art date
Application number
HRP20150136TT
Other languages
English (en)
Croatian (hr)
Inventor
Elena Barbanti
Carla Caccia
Patricia Salvati
Francesco Velardi
Tiziano Ruffilli
Luigi Bogogna
Original Assignee
Newron Pharmaceuticals S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37101658&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20150136(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Newron Pharmaceuticals S.P.A. filed Critical Newron Pharmaceuticals S.P.A.
Publication of HRP20150136T1 publication Critical patent/HRP20150136T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C233/08—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/12—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups
    • C07C233/13—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/10—Preparation of carboxylic acid amides from compounds not provided for in groups C07C231/02 - C07C231/08
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/16—Preparation of optical isomers
    • C07C231/18—Preparation of optical isomers by stereospecific synthesis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HRP20150136TT 2006-06-19 2007-06-08 Postupak dobivanja 2-[4-(3- i 2-fluorbenziloksi)benzilamino]propanamida HRP20150136T1 (xx)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06012565 2006-06-19
PCT/EP2007/005105 WO2007147491A1 (en) 2006-06-19 2007-06-08 Process for the production of 2- [4 - ( 3- and 2-flu0r0benzyl0xy) benzylamin0] propan amides
EP07764601.6A EP2029524B1 (en) 2006-06-19 2007-06-08 Process for the production of 2- [4 - ( 3- and 2-fluorobenzyloxy) benzylamino] propan amides

Publications (1)

Publication Number Publication Date
HRP20150136T1 true HRP20150136T1 (xx) 2015-03-13

Family

ID=37101658

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20150136TT HRP20150136T1 (xx) 2006-06-19 2007-06-08 Postupak dobivanja 2-[4-(3- i 2-fluorbenziloksi)benzilamino]propanamida
HRP20161456TT HRP20161456T1 (hr) 2006-06-19 2016-11-03 2-[4-(3- i 2-fluorbenziloksi)benzilamino]propanamidi visoke čistoće, namijenjenu upotrebi kao medikamenti i farmaceutske formulacije koje ih sadrže

Family Applications After (1)

Application Number Title Priority Date Filing Date
HRP20161456TT HRP20161456T1 (hr) 2006-06-19 2016-11-03 2-[4-(3- i 2-fluorbenziloksi)benzilamino]propanamidi visoke čistoće, namijenjenu upotrebi kao medikamenti i farmaceutske formulacije koje ih sadrže

Country Status (26)

Country Link
US (2) US8076515B2 (https=)
EP (2) EP2474521B1 (https=)
JP (2) JP5240476B2 (https=)
KR (2) KR101410291B1 (https=)
CN (2) CN101472880B (https=)
AR (1) AR061510A1 (https=)
AU (1) AU2007263328C1 (https=)
BR (1) BRPI0712936B8 (https=)
CA (1) CA2653012C (https=)
CY (2) CY1115951T1 (https=)
DK (2) DK2474521T3 (https=)
EA (2) EA017123B1 (https=)
ES (2) ES2527437T3 (https=)
HR (2) HRP20150136T1 (https=)
HU (1) HUE030233T2 (https=)
IL (1) IL195294A (https=)
LT (1) LT2474521T (https=)
MX (2) MX2008015704A (https=)
NO (2) NO342018B1 (https=)
NZ (2) NZ595737A (https=)
PL (2) PL2474521T3 (https=)
PT (2) PT2474521T (https=)
RS (2) RS53824B1 (https=)
SI (2) SI2474521T1 (https=)
TW (2) TWI393700B (https=)
WO (1) WO2007147491A1 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1658062T3 (da) * 2003-08-25 2010-05-31 Newron Pharm Spa Alfa-aminoamid-derivater anvendelige som anti-inflammatoriske midler
HUE030233T2 (en) * 2006-06-19 2017-04-28 Newron Pharm Spa High purity 2- [4- (3- and 2-fluorobenzyloxy) benzylamino] propanamides for use as medicaments and pharmaceutical compositions containing them
US8530701B2 (en) 2007-12-11 2013-09-10 Newron Pharmaceuticals, S.P.A. High purity 2-[4-(3- OR 2-fluorobenzyloxy)benzylamino]propanamides and methods of use thereof
EP2314569A1 (en) 2009-10-22 2011-04-27 Merck Patent GmbH Novel polymorphic forms of (S)-2-[4-(3-Fluoro-benzyloxy)-benzylamino]-propionamide mesylate salt and processes of manufacturing thereof
SI2563355T1 (sl) * 2010-04-27 2016-10-28 Newron Pharmaceuticals S.P.A. Postopek za izdelavo metansulfonatnih soli ralfinamida ali njihovih R-enantiomerov
KR20150090100A (ko) 2012-12-03 2015-08-05 에프. 호프만-라 로슈 아게 스테아로일-CoA 불포화화효소 1(에스씨디 1)의 억제제로서의 치환된 이속사졸 아마이드 화합물
US9475757B2 (en) 2013-05-03 2016-10-25 Council Of Scientific & Industrial Research Synthesis of anti-Parkinson agent
CN104292128A (zh) * 2014-07-01 2015-01-21 南京正科制药有限公司 一种沙芬酰胺晶型a
JP6466109B2 (ja) * 2014-09-09 2019-02-06 東ソー・ファインケム株式会社 ２−ベンジルオキシ−５−（トリフルオロメチル）ピリミジン誘導体及びその製造方法
CN105017060B (zh) * 2015-07-03 2017-06-16 南京正大天晴制药有限公司 一种沙芬酰胺新晶型及其制备方法
CN113072436A (zh) * 2015-07-24 2021-07-06 上海医药集团股份有限公司 一种苄基芳基醚的制备方法
CN105061245A (zh) * 2015-08-25 2015-11-18 成都维恒医药科技有限公司 一种高纯度沙芬酰胺的制备方法
CN106220525A (zh) * 2016-07-31 2016-12-14 合肥远志医药科技开发有限公司 一种工业化沙芬酰胺甲磺酸盐的制备方法
CN106336363B (zh) * 2016-08-22 2018-10-30 上海医药集团股份有限公司 一种沙芬酰胺甲磺酸盐晶型c及其制备方法
CN106565521B (zh) * 2016-08-24 2019-03-08 浙江美诺华药物化学有限公司 (s)-2-[3-(3-氟苄基)-4-(3-氟苄氧基)苄氨基]丙酰胺及其盐的制备方法
CN106596828B (zh) * 2016-12-15 2018-09-25 扬子江药业集团有限公司 一种甲磺酸沙芬酰胺有关物质的检测方法
CN107271600B (zh) * 2017-07-28 2019-01-25 成都百裕制药股份有限公司 一种4-(3-氟苄氧基)苯甲醛中异构体杂质含量的检测方法
CN107759487A (zh) * 2017-11-23 2018-03-06 江苏恒盛药业有限公司 一种沙芬酰胺盐酸盐及其一种晶型以及制备方法
CN107857713A (zh) * 2017-11-23 2018-03-30 江苏恒盛药业有限公司 一种沙芬酰胺氢溴酸盐及其一种晶型
WO2019167085A1 (en) * 2018-03-01 2019-09-06 Msn Laboratories Private Limited, R&D Center Process for the preparation of (s)-2-[[4-[(3-fluorophenyl)methoxy]phenyl]methyl]amino propanamide methanesulfonate
US11111208B2 (en) 2019-06-17 2021-09-07 RK Pharma Solutions LLC Process for the preparation of safinamide mesylate intermediate
EP3772510B1 (en) * 2019-08-06 2024-02-14 Medichem, S.A. Process for preparing safinamide
CN111122736B (zh) * 2019-12-30 2021-03-12 北京鑫开元医药科技有限公司海南分公司 一种用于检测布瓦西坦中间体中对映异构体的方法
CN113214097B (zh) * 2020-01-21 2022-08-30 厦门大学 治疗阿尔茨海默病的化合物
CN112028754A (zh) * 2020-06-17 2020-12-04 浙江美诺华药物化学有限公司 一种甲磺酸沙芬酰胺中间体的制备方法
CN114088830B (zh) * 2021-11-10 2022-09-23 石家庄四药有限公司 一种4-(3-氟苄氧基)苯甲醛中异构体的检测方法
CN117923998A (zh) * 2022-10-24 2024-04-26 中国石油化工股份有限公司 苯甲醛及其衍生物的制备方法
CN116008439B (zh) * 2023-02-20 2023-10-27 山东绿叶制药有限公司 一种检测2,6-二氧杂螺[4,5]癸烷类化合物或其盐中杂质的方法
CN121548409A (zh) 2023-07-25 2026-02-17 印塔斯制药有限公司 沙芬酰胺的口腔分散药物固体剂型

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL94466A (en) * 1989-05-25 1995-01-24 Erba Carlo Spa Pharmaceutical preparations containing the history of A-amino carboxamide N-phenylalkyl are converted into such new compounds and their preparation
GB9727523D0 (en) 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Alpha-aminoamide derivatives useful as analgesic agents
EP0974351A3 (en) * 1998-04-24 2000-12-13 Jouveinal Medicament for preventing and treating gastrointestinal damage
AU4961001A (en) 2000-03-31 2001-10-15 Cocensys Inc Aminopyridines and their use as anticonvulsants and sodium channel blockers
DK1423168T3 (da) * 2001-09-03 2006-05-15 Newron Pharm Spa Farmaceutisk præparat omfattende gabapentin eller en analog deraf og et alfa-aminoamid og dets analgetiske anvendelse
EP1438956A1 (en) * 2003-01-16 2004-07-21 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful as antimigraine agents
WO2004066987A2 (en) * 2003-01-30 2004-08-12 Dynogen Pharmaceuticals, Inc. Use of sodium channel modulators for treating gastrointestinal tract disorders
AU2004207010A1 (en) * 2003-01-30 2004-08-12 Dynogen Pharmaceuticals, Inc. Methods of treating lower urinary tract disorders using sodium channel modulators
AR044007A1 (es) 2003-04-11 2005-08-24 Newron Pharmaceuticals Inc Metodos para el tratamiento de la enfermedad de parkinson
TW200507850A (en) * 2003-07-25 2005-03-01 Kyowa Hakko Kogyo Kk Pharmaceutical composition
DK1658062T3 (da) * 2003-08-25 2010-05-31 Newron Pharm Spa Alfa-aminoamid-derivater anvendelige som anti-inflammatoriske midler
EP1524267A1 (en) 2003-10-15 2005-04-20 Newron Pharmaceuticals S.p.A. Substituted benzylaminoalkylene heterocycles
EP1557166A1 (en) * 2004-01-21 2005-07-27 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of lower urinary tract disorders
EP1588704A1 (en) * 2004-04-22 2005-10-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders
DK1809271T5 (da) * 2004-09-10 2010-12-06 Newron Pharm Spa Anvendelse af (R)-(halogenbenzyloxy)benzylaminopropanamider som natrium- og/eller calciumkanalselektive modulatorer
EP1870097A1 (en) * 2006-06-15 2007-12-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
HUE030233T2 (en) * 2006-06-19 2017-04-28 Newron Pharm Spa High purity 2- [4- (3- and 2-fluorobenzyloxy) benzylamino] propanamides for use as medicaments and pharmaceutical compositions containing them
US8530701B2 (en) * 2007-12-11 2013-09-10 Newron Pharmaceuticals, S.P.A. High purity 2-[4-(3- OR 2-fluorobenzyloxy)benzylamino]propanamides and methods of use thereof
NZ586182A (en) * 2007-12-19 2012-02-24 Newron Pharm Spa Alpha-aminoamide derivatives useful in the treatment of psychiatric disorders

Also Published As

Publication number Publication date
SI2029524T1 (sl) 2015-03-31
KR101410291B1 (ko) 2014-06-20
DK2029524T3 (da) 2015-02-23
EP2029524B1 (en) 2014-11-26
CN103284984A (zh) 2013-09-11
TW200815322A (en) 2008-04-01
SI2474521T1 (sl) 2016-12-30
EA025326B1 (ru) 2016-12-30
IL195294A (en) 2015-03-31
IL195294A0 (en) 2009-08-03
RS55464B1 (sr) 2017-04-28
JP2009541232A (ja) 2009-11-26
KR20090021392A (ko) 2009-03-03
NZ572798A (en) 2011-11-25
LT2474521T (lt) 2016-11-25
TWI393700B (zh) 2013-04-21
CN103284984B (zh) 2016-08-03
AU2007263328B2 (en) 2012-03-22
CN101472880B (zh) 2013-04-24
CA2653012C (en) 2014-08-05
NO20171916A1 (no) 2009-01-16
HRP20161456T1 (hr) 2016-12-16
PL2474521T3 (pl) 2017-01-31
TWI412512B (zh) 2013-10-21
BRPI0712936B8 (pt) 2021-05-25
BRPI0712936A2 (pt) 2012-12-18
NZ595737A (en) 2013-04-26
NO342644B1 (no) 2018-06-25
KR101491541B1 (ko) 2015-02-09
US20120157712A1 (en) 2012-06-21
JP5240476B2 (ja) 2013-07-17
AU2007263328A1 (en) 2007-12-27
CN101472880A (zh) 2009-07-01
CY1115951T1 (el) 2017-01-25
PT2474521T (pt) 2016-11-10
EP2474521B1 (en) 2016-08-10
PT2029524E (pt) 2015-03-09
WO2007147491A1 (en) 2007-12-27
HUE030233T2 (en) 2017-04-28
JP5795342B2 (ja) 2015-10-14
DK2474521T3 (en) 2016-10-31
US8278485B2 (en) 2012-10-02
NO342018B1 (no) 2018-03-12
HK1130245A1 (en) 2009-12-24
EP2474521A1 (en) 2012-07-11
ES2527437T3 (es) 2015-01-26
TW201313662A (zh) 2013-04-01
US20090156678A1 (en) 2009-06-18
EP2029524A1 (en) 2009-03-04
EA200970028A1 (ru) 2009-06-30
MX2008015704A (es) 2009-01-09
NO20090231L (no) 2009-01-16
CY1118113T1 (el) 2017-06-28
EA201101308A1 (ru) 2012-02-28
US8076515B2 (en) 2011-12-13
KR20140027563A (ko) 2014-03-06
AU2007263328C1 (en) 2012-09-06
MX342698B (es) 2016-10-10
ES2602069T3 (es) 2017-02-17
AR061510A1 (es) 2008-09-03
RS53824B1 (sr) 2015-06-30
AU2007263328A2 (en) 2009-02-19
CA2653012A1 (en) 2007-12-27
BRPI0712936B1 (pt) 2021-02-23
PL2029524T3 (pl) 2015-04-30
EA017123B1 (ru) 2012-10-30
JP2013139446A (ja) 2013-07-18

Similar Documents

Publication Publication Date Title
HRP20150136T1 (xx) Postupak dobivanja 2-[4-(3- i 2-fluorbenziloksi)benzilamino]propanamida
EP1890546A4 (en) COMPOSITION FOR INCREASING THE BIOLOGICAL AVAILABILITY OF CURCUMIN
EP2136768A4 (en) Structured surfactant compositions
DOP2007000084A (es) Derivados de dihidropirazolopirimidinona
EP2120573A4 (en) piperidine
PT1962805T (pt) Composições de anti-infeciosos baseadas em lípidos para tratamento de infeções pulmonares
DK1981859T3 (da) Fremstilling af delmopinol
CR10562A (es) Nuevos derivados de piridazina
DOP2010000044A (es) Derivado de oxopirazina y herbicida
EP2445345A4 (en) benzamide derivatives
LT2966175T (lt) Farmacinės kompozicijos turinčios korteksolono-17-alfa-propionato
EP1877694A4 (en) FOLDING HINGE
FI20075975A0 (fi) Rainan mittaus
DK2114147T3 (da) Reduktion af bivirkninger af tramadol
CR10809A (es) Derivados de heteroaril-pirrolidinil-y-piperidinil-cetona
PT1850664E (pt) Formulação de cápsulas
BRPI0917210A2 (pt) exoterma controlada de formulações de cianocrilato
JP2006122056A5 (ja) β-グルカンの使用
BRPI0811132A2 (pt) Preparação de catalisadores de paládio-ouro
DK2170292T3 (da) Atazanavirholdige sammensætninger i tabletform
EP2043623A4 (en) NANOPARTICLE FORMULATIONS OF MODAFINIL
NO20055643D0 (no) Preparation of lodixanol
ATE523493T1 (de) 2-(1-oxo-1h-isochinolin-2-yl) acetamid-derivate
EP1906944A4 (en) SKI ANDRIN-B-PREPARATION
ATE514685T1 (de) Herbizid wirksame 4- (3-aminobenzoyl) -5- cyclopropylisoxazole